Specify a stock or a cryptocurrency in the search bar to get a summary
StageZero Life Sciences Ltd
SZLSFStageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada. Address: 70 East Beaver Creek Road, Richmond Hill, ON, Canada, L4B 3B2
Analytics
WallStreet Target Price
1.75 CADP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SZLSF
Dividend Analytics SZLSF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SZLSF
Stock Valuation SZLSF
Financials SZLSF
Results | 2019 | Dynamics |